Radionuclide Drug Conjugate DesignRDC (Radionuclide Drug Conjugate) is an innovative and rapidly evolving multifunctional radiopharmaceutical. Composed of four components, including radionuclide, chelator, linker, and targeting molecule, RDC can accurately identify the diseased cells, image the binding cells, and damage the tumor.Bifunction of RDCDiagnostic ImagingNuclear imaging, providing detailed imaging at the molecular and cellular level, can accurately diagnose and analyze cancer. Both PET (Positron Emission Computed Tomography) and SPECT (Single-Photon Emission Computed Tomography), which can detect a pair of gamma rays emitted from the radiopharmaceutical that binds to target cells, are widely used in nuclear imaging to visualize tumors and monitor tumor progression.Nuclear Medicine TherapyAs the targeted molecule in RDC can bind to the specific molecules expressed by the cancer cells, the RDC can move to the targeted tissue rapidly and gather at that part. The alpha-emitting radionuclide with high energy is capable to kill the cancer cells. Through general radiotherapy, the treatment results are mainly dependent on the sensitivity difference between diseased tissue, while the RDC is more effective and harmless to the patients.Cancers Treated by RDCCancer is one of the most noted diseases today. However, neither the existing chemotherapy nor radiotherapy can perfectly cause precise damage to tumor cells. RDC, as a novel radiopharmaceutical, can accurately identify and kill tumor cells. A number of RDC have developed to be applied in tumor imaging and treatment.
Be the first person to like this.
